碧迪医疗剥离诊断与生物科学部门,估值约300亿美元

新京报
08 Feb

拆分传言成真。美国医疗器械制造商碧迪医疗(Becton Dickinson,简称BD)当地时间2月6日宣布,拆分其诊断与生物科学部门。此前有媒体报道,该部门估值约为300亿美元。这也是碧迪医疗在剥离糖尿病护理业务近三年后的又一次瘦身。在近年的多次拆分与并购中,扭转净利润下滑的颓势,是这家器械巨头的当务之急。剥离预计于2026年完成在本周四举行的电话财报会议上,碧迪医疗明确将剥离诊断与生物科学部门。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10